Time and money: An analysis of the legislative efforts to address the prescription drug shortage crisis in America

Journal of Legal Medicine

Volumn 33, Issue 2, 2012, Pages 235-251

  Born, Kevin ^a  

^a SOUTHERN ILLINOIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; COMMERCIAL PHENOMENA; DRUG INDUSTRY; DRUG LEGISLATION; FOOD AND DRUG ADMINISTRATION; HUMAN; UNITED STATES;

COMMERCE; DRUG INDUSTRY; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84862553920     PISSN: 01947648     EISSN: 1521057X     Source Type: Journal    
DOI: 10.1080/01947648.2012.686801     Document Type: Review

References (57)

1. Energy and Commerce, 112th Cong. 8 (2011) (testimony of Richard Paoletti, Vice President Lancaster General Health) (quoting Jacqueline Evans, Cancer Care for Women) [hereinafter Paoletti Testimony], available at http://republicans. energycommerce. house.gov/Media/file/Hearings/Health/092311%20Drug%20Shortages/ Paoletti Testimony.pdf.
2. Susan Kennedy, Op-Ed., Drug Shortage: What Can I Do?, USA TODAY, Sept. 13, 2011, http://www. usatoday.com/news/opinion/forum/story/2011-09-13/cancer- drug-shortage/50389896/1.
3. Institute for Safe Medication Practices, Drug Shortages: National Survey Reveals High Level of Frus tration, Low Level of Safety, 15 ISMP MEDICATION SAFETY ALERT! 1, 3 (2010) [hereinafter ISMP Report], available at http://www.ismp.org/newsletters/acutecare/articles/20100923.asp.
4. Center for Drug Evaluation and Research Drug Shortage Workshop, available at http://www.fda.gov/Drugs/NewsEvents/ucm265968.htm.
5. Joseph M. Hill & Cynthia Reilly, Can the United States Ensure an Adequate Supply of Critical Medications?, 1 FOOD & DRUG POL'Y FORUM. 1, 1 (2011).
6. Examining the Increase in Drug Shortages: Hearing on H.R. 2245 Before the Subcomm. on Health of the H. Comm. on Energy and Commerce, 112th Cong. 2-3 (2011) (statement of Howard Koh, Assistant Secretary for Health) [hereinafter Koh Testimony], available at http://republicans.energycommerce. house.gov/Media/file/Hearings/Health/092311%20Drug%20Shortages/Kohtestimony.pdf.
7. Drug Shortages Hit Record Levels in 2011, 2012 May Not Be Much Better, MODERN MED., http://www.modernmedicine.com/modernmedicine/article/articleDetail. jsp?id=755523 (last visited Feb. 1, 2012).
8. Maryn McKenna, Hospital Pharmacists Scrambling Amid Vast Drug Shortages: Emergency Physicians Between Roc and a Hard Place, 56 ANNALS EMERGENCY MED. 13A (2011).
9. Koh Testimony, supra note 10, at 2.
10. Preserving Access to Life-Saving Medications Act, S. 296, 112th Cong. (2011);
11. Preserving Access to Life-Saving Medications Act of 2011, H.R. 2245, 112th Cong. (2011).
12. Koh Testimony, supra note 10, at 2.
13. Rola Kaakeh et al., Impact of Drug Shortages on U.S. Health Systems, 68 AM. J. HEALTH SYST. PHARM. 1811, 1811 (2011).
14. Koh Testimony, supra note 10, at 2, 6, 7.
15. Kaakeh et al., supra note 19, at 1811.
16. Paoletti Testimony, supra note 1, at 7.
17. U.S. FOOD AND DRUG ADMIN., A REVIEW OF FDA'S APPROACH TO MEDICAL PRODUCT SHORTAGES 10, 13 (2011), available at http://www.fda.gov/downloads/AboutFDA/ ReportsManualsForms/Reports/UCM277755.pdf
18. Koh Testimony, supra note 10, at 2, 6, 7;
19. Paoletti Testimony, supra note 1, at 6.
20. Mike Mitka, FDA, US Hospital and Pharmacy Groups Report Drug Shortages a Growing Problem, 306 J.A.M.A. 1069, 1069 (2011).
21. Paoletti Testimony, supra note 1, at 2.
22. H. Comm. on Energy and Commerce, 112th Cong. 2 (2011) (statement of Charles Penley of the American Society of Oncology) [hereinafter Penley Testimony], available at http://republicans.energy commerce.house.gov/Media/ file/Hearings/Health/092311%20Drug%20Shortages/Penley Testimony. pdf.
23. Erin R. Fox et al., ASHP Guidelines on Managing Drug Product Shortages in Hospitals and Health Systems, 66 AM. J. HEALTH-SYST. PHARM. 1399, 1401 (2009).
24. Hearing Before the S. Comm. on Health Educ. Labor and Pensions, 112th Cong. 2 (2011) (statement of Deborah Autor, Commissioner for Global Regulatory Operations and Policy, FDA) [hereinafter Autor Testimony], available at http://help.senate.gov/imo/media/doc/Autor.pdf.
25. Premier, Inc., Navigating Drug Shortages in American Healthcare: A Premier Healthcare Al liance Analysis (Mar. 2011), available at http://www.premierinc.com/about/news/11-mar/drug-shortage-white-paper-3-28-11. pdf;
26. Examining the Increase in Drug Shortages: Hearing on H.R. 2245 Before the Subcomm. on Health of the H. Comm. on Energy and Commerce, 112th Cong. 7 (2011) (statement of Michael Alkire, Chief Operating Officer Premier Healthcare Alliance) [hereinafter Alkire Testimony], available at http://republicans. energycommerce.house.gov/Media/file/Hearings/Health/092311%20Drug%20Shortages/ Alkire Testimony.pdf.
27. Valerie Jensen et al., FDA's Role in Responding to Drug Shortages, 59 AM. J. HEALTH SYS. PHARM. 1423, 1424 (2002);
28. Tara D. Mullins & Aaron M. Cook, Drug Shortages: Causes and Cautions, 34 ORTHOPEDICS 712, 713 (2011).
29. KEVIN HANINGER ET AL., ECONOMIC ANALYSIS OF THE CAUSES OF DRUG SHORTAGES 1 (2011), available at http://aspe.hhs.gov/sp/reports/2011/DrugShortages/ib.pdf;
30. Glenn Singer & Nancy McVicar, Hurricane Georges Leaves Shortage of Heart Medicine, SUN SENTI-NAL, Oct. 29, 1998, http://articles.sun-sentinel.com/ 1998-10-29/news/9810290017 1 heart-patients-chest-pain-nitroglycerin.
31. Walter Chambliss et al., Mitigating the Impact of Medication Shortage on Public Health, 51 J. AM. PHARMACISTS ASS'N 574, 575 (2011).
32. Jensen et al., supra note 51, at 1423.
33. Examining the Increase in Drug Shortages: Hearing on H.R. 2245 Before the Subcomm. on Health of the H. Comm. on Energy and Commerce, 112th Cong. 2 (2011) (testimony of Sandy Kweder, Deputy Director of the FDA office of New Drugs) [hereinafter Kweder Testimony], available at http://republicans.energycommerce. house.gov/hearings/hearingdetail.aspx?NewsID=8926.
34. Hearing on H.R. 2245 Before the Subcomm. on Health of the H. Comm. on Energy and Commerce, 112th Cong. 2, 9 (2011) (statement of Kevin Colgan on behalf of the American Society of Health System Pharmacists) [hereinafter Colgan Testimony], available at http://republicans.energy commerce.house.gov/Media/ file/Hearings/Health/092311%20Drug%20Shortages/Colgan Testimony. pdf; Paoletti Testimony, supra note 1, at 2, 6.
35. Koh Testimony, supra note 10, at 2, 10 (99 shortages prevented from Jan. 1, 2010 through Sept. 2011); Health and Human Services, Fact Sheet: Continued Progress on Reducing Drug Shortages, http://www.hhs.gov/news/press/2011pres/12/ 20111215a fda.html (last visited Feb. 1, 2012) (96 prevented since Oct. 31, 2011, 233 total since Jan. 1, 2010).
36. Preserving Access to Life-Saving Medications Act, S. 296, 112th Cong. § 2(a) (2011);
37. Preserving Access to Life-Saving Medications Act of 2011, H.R. 2245, 112th Cong. § 2(a) (2011).
38. Reducing Prescription Drug Shortages, Exec. Order No. 13588, 76 Fed. Reg. 68, 295 (Nov. 3, 2011), available at http://www.whitehouse.gov/the-press- office/2011/10/31/executive-order-reducing-prescription-drug-shortages.
39. Press Release, Office of the Press Secretary, Fact Sheet: Obama Administration Takes Action to Reduce Prescription Drug Shortages in the US (Oct. 31, 2011), available at http://www.whitehouse.gov/the-press-office/2011/ 10/31/fact-sheet-obama-administration-takes-action-reduce-prescription-drug-sh.
40. Examining the Increase in Drug Shortages: Hearing on H.R. 2245 Before the Subcomm. on Health of the H. Comm. on Energy and Commerce, 112th Cong. 3 (2011) (statement of Jonathan M. Kafer, Vice President Sales and Marketing, Teva Health Systems) [hereinafter Kafer Testimony], avail able at http://republicans.energycommerce.house.gov/Media/file/Hearings/Health/ 092311%20Drug% 20Shortages/Kafer Testimony. pdf.
41. AM. SOC'Y HEALTH-SYS. PHARM., DRUG SHORTAGES SUMMIT SUMMARY REPORT 3 (2010) [hereinafter SUMMIT SUMMARY REPORT], available at http://www.ashp.org/ drugshortages/summitreport.
42. Frequently Asked Questions on Prescription Drug User Fees, FDA, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ ucm069943.htm (last visited Feb. 1, 2012).
43. Prescription Drug User Fee Rates Notice, 72 Fed. Reg. 58, 103 (Oct. 12, 2007), available at http://edocket.access.gpo.gov/2007/pdf/07-5052.pdf.
44. Colgan Testimony, supra note 78, at 10.
45. HANINGER ET AL., supra note 53, at 14.
46. Penley Testimony, supra note 32, at 9;
47. Colgan Testimony, supra note 78, at 10;
48. Paoletti Testimony, supra note 1, at 8.
49. Penley Testimony, supra note 32, at 9.
50. HANINGER ET AL., supra note 53, at 8-9, 13.
51. HANINGER ET AL., supra note 53, at 8-9, 13;
52. A REVIEW OF FDA'S APPROACH, supra note 24, at 13-16.
53. Kafer Testimony, supra note 104;
54. SUMMIT SUMMARY REPORT, supra note 105.
55. Gardiner Harris, Shipments from Abroad to Help Ease Shortage of Two Can cer Drugs, Feb. 21, 2012, http://www.nytimes.com/2012/02/22/health/policy/fda- approves-imports-amid-shortage-of-2-cancer-drugs.html? r=1.
56. Gardiner Harris, Herapin Contamination May Have Been Deliberate, FDA Says, N.Y. TIMES, Apr. 30, 2008, http://www.nytimes.com/2008/04/30/health/ policy/30heparin.html.
57. Securing the Pharmaceutical Supply Chain: Hearing Before the S. Comm. on Health Educ. Labor and Pensions, 112th Cong. (2011) (testimony of Deborah Autor, Commissioner for Global Regulatory Operations and Policy, FDA) available at http://www.help.senate.gov/hearings/hearing/?id=3fe78bef-5056-9502-5da8- cf290af9c334